ChantixThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

625 records returned

The Cost-Effectiveness of an Extended Course (12 + 12 Weeks) of Varenicline Compared with Other Available Smoking Cessation Strategies in the United States: An Extension and Update to the BENESCO ModelEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: A total of 12 weeks of varenicline followed by a further 12-week course for successful quitters is a highly cost-effective alternative compared with currently available smoking cessation options. (Source: Value in Health)
Source: Value in Health - November 14, 2009 Category: Global & Universal Authors: Chris Knight, Paul Howard, Christine L. Baker, Jeno P. Marton Source Type: journals

Varenicline: First report of liver injury: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 11, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Varenicline May Not Be Linked to Increased Risk for Self-HarmEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A cohort study shows no clear evidence of an increased risk for fatal or nonfatal self-harm or depression with varenicline use, but a 2-fold increased risk cannot be ruled out. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2009 Category: Consumer Health News Tags: Psychiatry Source Type: news

Varenicline Effective for Highly Nicotine-Dependent Smokers With COPDEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Varenicline was associated with a 42.3% quit rate at 40 weeks for the hard-to-treat population of smokers with mild to moderate chronic obstructive pulmonary disease (COPD). Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2009 Category: Consumer Health News Tags: Pulmonary Medicine Source Type: news

Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX(R) (Varenicline) Compared With PlaceboEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 5, 2009 Category: Consumer Health News Tags: Smoking / Quit Smoking Source Type: news

Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX(R) (Varenicline) Compared With PlaceboEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p (Source: Asthma / Respiratory News From Medical News Today)
Source: Asthma / Respiratory News From Medical News Today - November 5, 2009 Category: Respiratory Medicine Tags: Smoking / Quit Smoking Source Type: news

Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX (Varenicline) Compared With PlaceboEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Findings from Pfizer-Sponsored Study Presented as Late-Breaker at American College of Chest Physicians Annual Meeting SAN DIEGO--(BUSINESS WIRE)--Nov 4, 2009 - New study results showed that 42.3 percent of smokers with mild-to-moderate... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 5, 2009 Category: Pharmaceuticals Source Type: clinical trials

CHEST: Varenicline Helps Patients with COPD Quit Smoking (CME/CE, with video)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN DIEGO (MedPage Today) -- Much as it aided the general population of smokers, varenicline (Chantix) helped patients with chronic obstructive pulmonary disorder (COPD) quit too, a randomized trial showed. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - November 4, 2009 Category: Journals (General) Source Type: info

Study: Varenicline Safe for Depressed SmokersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
MONTREAL — Despite postmarketing concerns about the psychiatric side effects of varenicline for smoking cessation, the medication appears to be safe in patients who are depressed or at risk for depression, Jennifer B. McClure, Ph.D., reported at the annual meeting of the Society of Behavioral Medicine. (Source: Clinical Psychiatry News)
Source: Clinical Psychiatry News - November 1, 2009 Category: Psychiatry Authors: KATE JOHNSON Tags: Addiction Psychiatry Source Type: journals

Varenicline: First report of acute generalised exanthematous pustulosis: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 31, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Effect of the alpha4beta2( *) nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We studied the effects of 1mg/kg doses of nicotine and the alpha4beta2* nicotinic acetylcholine receptor (nAChR) partial agonist, varenicline, on extracellular dopamine (DA) levels in the nucleus accumbens (NuAcc) of lentivirally vectorized male mice. Three separate experimental groups were injected with a lentiviral vector transducing the ventral tegmental area (VTA): wild-type C57BL/6J mice with a vector expressing eGFP only, beta2 knock-out mice (beta2KO) with the eGFP-only vector, and beta2KO mice with a bi-cistronic vector reintroducing beta2 and eGFP into the VTA as recently described (Maskos et al., 2005). Our r...
Source: Neuropharmacology - October 31, 2009 Category: Drugs & Pharmacology Authors: Reperant C, Pons S, Dufour E, Rollema H, Gardier AM, Maskos U Tags: Neuropharmacology Source Type: journals

Chantix slash costsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The maker of Lipitor, Viagra and anti-smoking drug Chantix is $2.88 billion in the black after slashing costs (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 21, 2009 Category: Drugs & Pharmacology Source Type: news

Varenicline: Mania: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 12, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Varenicline link to self harm not confirmedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 12, 2009 Category: Drugs & Pharmacology Tags: Research article Source Type: journals

Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. - Gunnell D, Irvine D, Wise L, Davies C, Martin RM.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
OBJECTIVE: To determine whether varenicline, a recently licensed smoking cessation product, is associated with an increased risk of suicide and suicidal behaviour compared with alternative treatments bupropion and nicotine replacement therapy. DESIGN: Coho... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - October 11, 2009 Category: Global & Universal Tags: Home and Consumer Product Safety Source Type: info

Study Provides Boost for ChantixEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
British researchers say they found no evidence that the stop-smoking drug varenicline leads to depression or increased suicide risk. (Source: Alcohol, Tobacco and Other Drugs News)
Source: Alcohol, Tobacco and Other Drugs News - October 7, 2009 Category: Addiction Source Type: news

Varenicline takes the top spot in BelgiumEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 5, 2009 Category: Health Management Tags: Research article Source Type: journals

Smoking Cessation Drug Not Linked To An Increased Risk Of Self Harm Or DepressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
There is no strong evidence that the popular smoking cessation drug varenicline increases the risk of self harm or depression compared to other cessation products, according to new research published on http://www.bmj.com today. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 5, 2009 Category: Consumer Health News Tags: Smoking / Quit Smoking Source Type: news

No Link Between Suicide and Stop-Smoking Drugs (CME/CE)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Contrary to information that led the FDA and other regulatory agencies to release warnings about varenicline (Chantix), a new study has found "no clear evidence" of a relationship between the risk of suicide and the smoking-cessation drug. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 2, 2009 Category: Primary Care Source Type: news

No link found between popular smoking cessation drug and depressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
There is no strong evidence that the popular smoking cessation drug varenicline increases the risk of self harm or depression compared to other cessation products, according to a new study by researchers at the University of Bristol, published today on bmj.com. (Source: University of Bristol news)
Source: University of Bristol news - October 2, 2009 Category: Universities & Medical Training Authors: news_text Tags: Press releases Source Type: organizations

Smoking cessation drug "not linked to depression"Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
There is no strong evidence that the popular smoking cessation drug varenicline increases the risk of self harm or depression (Source: Nursing in Practice)
Source: Nursing in Practice - October 2, 2009 Category: Nursing Source Type: news

Research rejects smoking drug risksEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New research published into the varenicline, a drug used by people wanting to give up smoking, has shown it does not increase the risk of self harm or depression any more than its competitors (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 2, 2009 Category: Drugs & Pharmacology Source Type: news

Doubts on suicide-anti-smoking drug Chantix linkEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEW YORK (Reuters Health) - Despite earlier health agency warnings, there is no strong evidence that the anti-smoking drug Chantix raises the risk of suicidal thoughts or depression compared to other stop-smoking products, researchers reported Thursday in the British Medical Journal. (Source: Reuters: Health)
Source: Reuters: Health - October 2, 2009 Category: Consumer Health News Tags: healthNews Source Type: news

Doubts on Suicide-Anti-Smoking Drug Chantix LinkEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Despite earlier health agency warnings, there is no strong evidence that the anti-smoking drug Chantix raises the risk of suicidal thoughts or depression compared to other stop-smoking products, researchers reported Thursday in the British Medical Journal. Source: Reuters Health Related MedlinePlus Topics: Medicines, Quitting Smoking, Suicide (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 2, 2009 Category: Consumer Health News Source Type: consumer

Study Counters Warnings on Quit-Smoking DrugEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
No clear evidence found that Chantix has dangerous side effects, say UK researchers (Source: Forbes.com Health News)
Source: Forbes.com Health News - October 2, 2009 Category: Consumer Health News Source Type: news

'No Clear Evidence' That Chantix Increases Risk for Self-HarmEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 2, 2009 Category: Primary Care Tags: Medical News Source Type: info

Health News of the DayEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
is a daily summary made from the selected links I post on Twitter. It is in a bullet points format with links to the original sources which include 350 RSS feeds that produce about 2,500 items per day:Novo Nordisk's insulin Levemir was not associated with any increase in cancer in studies including 9,000 patients http://bit.ly/1pJY8UJAMA: Plain surgical mask prevents influenza as well as N95 respirator http://bit.ly/cSr2y - Doubtful."Safety Gurus: Penalize Doctors Who Don’t Follow the Rules" - WSJ http://bit.ly/2ttXpPAntismoking drug Chantix has been linked to suicide but a new study shows that such risk is nonexistent ...
Source: Clinical Cases and Images - October 2, 2009 Category: Journals (General) Tags: Health News of the Day Source Type: info

Study disputes MHRA warnings over varenicline suicide linkEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new study disputes claims of a link between the smoking cessation drug varenicline and an increased risk of suicide and suicidal behaviour. (Source: Pulse)
Source: Pulse - October 2, 2009 Category: Primary Care Tags: News Source Type: news

No Link Between Smoking Cessation Drug And Increased Risk Of Self Harm Or DepressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New research published today on bmj.com suggests there is no strong evidence that the popular smoking cessation drug varenicline increases the risk of self harm or depression compared to other cessation products. The newly introduced Varenicline is a smoking cessation product of proven effectiveness. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 2, 2009 Category: Consumer Health News Tags: Smoking / Quit Smoking Source Type: news

Study: Chantix Has Little or No Suicide RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Study: Chantix Has Little or No Suicide RiskCategory: Health NewsCreated: 10/2/2009 10:56:00 AMLast Editorial Review: 10/2/2009 10:56:57 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 2, 2009 Category: Cancer & Oncology Source Type: consumer

Study: Chantix Has Little or No Suicide RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Study: Chantix Has Little or No Suicide RiskCategory: Health NewsCreated: 10/2/2009 10:56:00 AMLast Editorial Review: 10/2/2009 10:56:57 AM (Source: MedicineNet Senior Health General)
Source: MedicineNet Senior Health General - October 2, 2009 Category: Geriatrics Source Type: consumer

Chantix Has Little or No Suicide RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Study: Chantix Has Little or No Suicide Risk (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 2, 2009 Category: Journals (General) Source Type: info

Study: Chantix Has Little or No Suicide RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Study: Chantix Has Little or No Suicide RiskCategory: Health NewsCreated: 10/2/2009 10:56:00 AMLast Editorial Review: 10/2/2009 10:56:57 AM (Source: MedicineNet Depression General)
Source: MedicineNet Depression General - October 2, 2009 Category: Psychiatry Source Type: consumer

Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research DatabaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: BMJ Area: News According to the authors of a cohort study published early online in the British Medical Journal, an increased risk of self-harm with varenicline cannot be ruled out. They do note however that their results 'provide some reassurance concerning its association with suicidal behaviour'. The MHRA issued a warning in December 2007, after reports of depression and suicidal thoughts among people prescribed varenicline; further warnings were issued in July and November 2008. Similar warnings have been issued by regulatory authorities worldwide, and the US FDA recently required the ma...
Source: NeLM - News - October 1, 2009 Category: Drugs & Pharmacology Source Type: organizations

Smoking Cessation Drug Likely Doesn't Raise Self-Harm OddsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The smoking cessation drug varenicline is likely not associated with increased risk of self-harm, although a two-fold increased risk cannot be ruled out, according to a study published Oct. 2 in BMJ. (Source: Modern Medicine)
Source: Modern Medicine - October 1, 2009 Category: Journals (General) Source Type: info

Chantix-Suicide Link QuestionedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Earlier this year, the FDA ordered a "black box" warning be added to the drugs Chantix (varenicline) and Zyban (bupropion), which are both used as aids in quitting smoking. ... (Source: About.com Depression)
Source: About.com Depression - October 1, 2009 Category: Psychiatry Source Type: consumer

Study: Chantix Has Little or No Suicide RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The antismoking drug Chantix has been linked to suicide and suicidal thoughts, but a new study shows that if such a risk exists it is likely to be very small. (Source: WebMD Health)
Source: WebMD Health - October 1, 2009 Category: Consumer Health News Source Type: news

Crossing Borders: Factors Affecting Differences in Cost-Effectiveness of Smoking Cessation Interventions between European CountriesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Although all INMBs were positive, there were significant differences across countries. These were primarily related to choice of discount rate and epidemiology of diseases. (Source: Value in Health)
Source: Value in Health - September 24, 2009 Category: Global & Universal Authors: Pepijn Vemer, Maureen P.M.H. Rutten-van Mölken Source Type: journals

Varenicline: Worsening psychosis: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - September 21, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Efficacy of pharmacotherapies for short-term smoking abstinence: A systematic review and meta-analysis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background: Smoking cessation has important immediate health benefits. The comparative short-term effectiveness of smoking cessation interventions is not well known. We aimed to determine the relative effectiveness of nicotine replacement therapy (NRT), bupropion and varenicline at 4 weeks post-target quit date. Methods: We searched 10 electronic medical databases (inception to October 2008). We selected randomized clinical trials [RCTs] evaluating interventions for our primary outcome of abstinence from smoking at at-least 4 weeks post-target quit date, with biochemical confirmation. We conducted random-effects odds ratio...
Source: Harm Reduction Journal - September 17, 2009 Category: Drugs & Pharmacology Authors: Edward MillsPing WuDean SpurdenJon EbbertKumanan Wilson Source Type: journals

Varenicline: First report of heart arrest: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - September 14, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

[Care Results in a Specialist Stop-Smoking Unit.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: A stop-smoking clinic that is designed according to SEPAR Recommendations is effective and has a good cost/effective ratio. PMID: 19758742 [PubMed - as supplied by publisher] (Source: Archivos de Bronconeumologia)
Source: Archivos de Bronconeumologia - September 13, 2009 Category: Cardiovascular & Thoracic Surgery Authors: Jiménez Ruiz CA, Mayayo Ulibarri M, Cicero Guerrero A, Amor Besada N, Ruiz Martín JJ, Cristóbal Fernández M, Astray Mochales J Tags: Arch Bronconeumol Source Type: journals

A Method for Educating Patients and Documenting Smoking Status in an Electronic Medical Record(October).Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Incorporating a smoking cessation template into existing progress notes and providing education during existing pharmacy referral visits is a simple and effective method to assist patients in achieving smoking cessation. PMID: 19737992 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - September 7, 2009 Category: Drugs & Pharmacology Authors: Ragucci KR, Shrader SP Tags: Ann Pharmacother Source Type: journals

Varenicline: First report of proximal myopathy: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - September 7, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

[Tolerability profile of varenicline in current medical practice.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: This retrospective study confirmed the tolerability issues for varenicline, identified during the phase II-phase III development program and confirmed afterwards. It raises the following questions: Should varenicline be prescribed as a second-line therapy? Is there a patient type for which varenicline would be more - or less - appropriate? Can the tolerability profile be improved by reducing dosage while maintaining the level of efficacy or by co-administering symptomatic treatment more systematically? These are questions that new studies evaluating varenicline tolerability should answer. PMID: 19740621 [Pu...
Source: Presse Medicale - September 6, 2009 Category: Journals (General) Authors: Dupont P, Gillet C, Guerin M, Kalamarides S, Larinier E, Meignan C, Moreau A, Guillaumin C, Perriot J Tags: Presse Med Source Type: journals

Cost Effectiveness of Varenicline in Belgium, Compared with Bupropion, Nicotine Replacement Therapy, Brief Counselling and Unaided Smoking Cessation: A BENESCO Markov Cost-Effectiveness AnalysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 1, 2009 Category: Drugs & Pharmacology Authors: Annemans, LievenNackaerts, KristiaanBartsch, PierrePrignot, JacquesMarbaix, Sophie Tags: Original Research Articles Source Type: journals

Recalls and Safety Alerts: Warning on Neuropsychiatric Effects from Smoking Cessation DrugsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
FDA is requiring that two drugs used to help people stop smoking carry new warnings about the risk of serious neuropsychiatric effects. The drugs are Chantix (varenicline) and Zyban (bupropion). The same warnings will be required for other bupropio... (Source: Food and Drug Adminstration (FDA): Patient Safety News)
Source: Food and Drug Adminstration (FDA): Patient Safety News - September 1, 2009 Category: American Health Source Type: news

MEDICAL NEWS & PERSPECTIVES: Varenicline Gets Stronger Warnings About Psychiatric Problems, Vehicle CrashesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: JAMA)
Source: JAMA - August 24, 2009 Category: Journals (General) Authors: Kuehn, B. M. Tags: Psychiatry, Psychiatry, Other, Public Health, Injury Prevention & Control, Tobacco, Quality of Care, Patient Safety/ Medical Error, Drug Therapy, Adverse Effects Medical News Perspectives Source Type: journals

[Treatment of tobacco dependence : A responsibility of psychiatry and addiction medicine.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The World Health Organisation (WHO) considers smoking to be the biggest avoidable health risk. The consumption of tobacco leads to health hazards and resulting diseases, the consequences of which are far more serious than those emanating from other addictive substances. Approximately 27% of the German adult population smoke regularly and the proportion of smokers addicted to tobacco or nicotine is estimated to be around 60%. Many of these smokers have undertaken numerous unsuccessful attempts at abstinence. A professional support for smokers who are motivated to give up smoking enhances the chances of success. The curr...
Source: Der Nervenarzt - August 20, 2009 Category: Neurology Authors: Batra A, Friederich HM, Lutz U Tags: Nervenarzt Source Type: journals

Lambert-Eaton myasthenic syndrome following varenicline (Chantix) useEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
No abstract. (Source: Muscle and Nerve)
Source: Muscle and Nerve - August 19, 2009 Category: Internal Medicine Authors: Elias Abou-Zeid, Stacy A. Rudnicki, Salah G. Keyrouz Source Type: journals